Clinical and economic aspects of chronic cerebral ischemia treatment
https://doi.org/10.37489/2588-0519-2024-4-46-54
EDN: NHHOEW
Abstract
Relevance. Chronic cerebral ischemia is a collective term describing various brain vascular lesions that develop without a stroke. For neuroprotective action and correction of cognitive impairment by acting on AMPA receptors, calcium salt of N- (5-hydroxynicotinoyl) — L-glutamic acid was synthesized. The effectiveness and safety of these drugs were initially demonstrated in biological models and were further confirmed in patients with chronic cerebral circulatory disorders.
Objective. To determine the optimal drug therapy for patients with chronic cerebral circulatory disorders on the basis of a comprehensive pharmacoeconomic analysis using the methods of analysis "cost of disease", "cost-effectiveness" and "cost-utility".
Materials and methods. Results of a multicenter randomized, double-blind, placebo-controlled trial of the efficacy and safety of calcium hydroxynicotinoyl glutamate (phase III); the results of studies on the effectiveness of ethylmethylhydroxypyridinesuccinate.
Results. According to the analysis the cost of the disease, "cost-effectiveness", "cost-utility" in patients with chronic cerebral circulatory disorders, it is more economically feasible to prescribe the drug calcium hydroxynicotinoyl glutamate.
Conclusions. According to the results of the study, the economic aspects of the rational use of health resources, as well as pharmacoeconomic parameters that determine the choice of tactics for the treatment of patients with chronic cerebral circulatory disorders, are of great importance.
About the Authors
A. V. Kiselev
N.N. Semenov Federal Research Center for Chemical Physics RAS
Russian Federation
Russian Federation
Alexey V. Kiselev - PhD, Cand. Sci. (Med.), Senior Researcher at the Laboratory of Chemical Physics of Biosystems (0152)
Moscow
A. L. Khokhlov
Yaroslavl State Medical University
Russian Federation
Russian Federation
Alexander L. Khokhlov — Dr. Sci (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Pharmacology and Clinical Pharmacology, Rector
Yaroslavl
S. V. Stovbun
N.N. Semenov Federal Research Center for Chemical Physics RAS
Russian Federation
Russian Federation
Sergey V. Stovbun — Dr. Sci (Phys.-Math.), Head of the Laboratory of Chemical Physics of Biosystems (0152)
Moscow
S. A. Speshilova
Yaroslavl State Medical University
Russian Federation
Russian Federation
Svetlana A. Speshilova — PhD, Cand. Sci. (Med.), Associate Professor of the Department of Pharmacology and Clinical Pharmacology
Yaroslavl
E. G. Lileeva
Yaroslavl State Medical University
Russian Federation
Russian Federation
Elena G. Lileeva — PhD, Cand. Sci. (Med), Head of the Basic Department of Innovative Pharmacy, Associate Professor of the Department of Pharmacology and Clinical Pharmacology
Yaroslavl
References
1. Management and economics of pharmacy: textbook / ed by VL Bagirov. Moscow: Medicine, 2004. (In Russ.)]. ISBN 5-225-04120-5.
2. Andrianova GN. Pharmacoeconomics [Text]: textbook / Andrianova GN, Karimova AA, Badaev FI; FSBEI USMU MOH Russia. Yekaterinburg: Publishing House of UGMU, 2017. (In Russ.)]. ISBN 978-5-89895-828-2.
3. ICD-10. International Statistical Classification of Diseases and Health-related Problems. 10th revision. Geneva. Moscow: WHO, Medicine; 1995. (In Russ.)].
4. Morbidity of the entire population of Russia in 2023: statistical materials. Deev IA, Kobyakova OS, Starodubov VI, et al. Moscow: FSBI "TSNIIOIZ" MOH Russia, 2024. (In Russ.)].
5. Resolution of the Council of Experts on the topic "New treatment options for patients with chronic cerebral ischemia", March 31, 2023. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(3):139-143. (In Russ.)]. doi: 10.14412/2074-2711-2023-3-139-143.
6. Cherdak MA, Mkhitaryan EA, Sharashkina NV, et al. Prevalence of cognitive impairment in older adults in the Russian Federation. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4-2):5-11. (In Russ.)]. doi: 10.17116/jnevro20241240425.
7. Amelina IP, Solov'eva ÉIu. Oxidative stress and inflammation as links in a chain in patients with chronic cerebrovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):106-114. (In Russ.)]. doi: 10.17116/jnevro2019119041106.
8. Demyanovskaya EG, Vasiliev AS, Shmyrev VI. Cognitive impairment in young and middle-aged patients. Lechaschi Vrach. 2023;5(26):48-54. (In Russ.)]. doi: 10.51793/OS.2023.26.5.008.
9. Parfenov VA. Vascular cognitive impairment and chronic cerebral ischemia (dyscirculatory encephalopathy). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(Suppl. 3):61-67. (In Russ.)]. doi: 10.14412/2074-2711-2019-3S-61-67.
10. Parfenov VA. Improving the management of patients with a diagnosis of chronic cerebral ischemia. Meditsinskiy sovet = Medical Council. 2020;(8):11-17. (In Russ.)]. doi: 10.21518/2079-701X-2020-8-11-17.
11. Malyavin AG, Tanashyan MM, Adasheva TV, et al. An interdisciplinary approach to assessing the risk of cerebrovascular accidents. Resolution of the Expert Council of the Russian Scientific Medical Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):96-99. (In Russ.)]. doi: 10.17116/jnevro202412409196.
12. Kamchatnov PR, Cheremin RA, Skipetrova LA, Chugunov AV. Cognitive disorders of vascular genesis in the practice of a therapist. Therapy. 2022;8(9):152-162. (In Russ.)]. doi: 10.18565/therapy.2022.9.152-162.
13. Захаров В.В., Слепцова К.Б., Мартынова О.О. Хроническая ишемия мозга: взгляд из ХХI века. РМЖ. 2021;5:45-49. [Zakharov VV, Sleptsova KB, Martynova OO. Chronic cerebral ischemia: a view from the ХХI century. RMJ. 2021;5:45-49. (In Russ.)].
14. Shishkova VN, Prikhodko VA, Okovityi SV. The choice of a modern neuroprotective drug as a basic strategy in the treatment of chronic cerebrovascular diseases. Meditsinskiy sovet = Medical Council. 2023;(10):41–49. (In Russ.)]. doi: 10.21518/ms2023-232.
15. Lokshina AB, Zakharov VV. Practical algorithms for managing patients with chronic cerebral ischemia. Effektivnaya Farmakoterapiya. 2019;15(19):24-28. (In Russ.)]. doi: 10.33978/2307-3586-2019-15-19-24-28.
16. Kashin AV. Efficacy and safety of mexidol in the treatment of cognitive dysfunction in patients with ischemic stroke. Byulleten’ Eksperimental’noj Biologii i Mediciny. 2012;1:36-38. (In Russ.)].
17. Zhuravleva MV, Prokofiev AB, Serebrova SYu, et al. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):119-124. (In Russ.)]. doi:10.17116/jnevro2020120061119.21.
18. Zakharov VV, Vakhnina NV. The use of Mexidol in patients with mild (moderate) cognitive impairment: results of a meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):82-88. (In Russ.)]. doi: 10.17116/jnevro202412401182.
19. Fedin AI, Zakharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.)]. doi: 17116/jnevro20211211117.
20. Solovyova EYu, Amelina IP, Kiselyov AV, Stovbun SV. New Generation of Glutamatergic Modulators in the Treatment of Cerebrovascular Disease. Nervous diseases. 2023;2:44-52. (In Russ.)]. doi: 10.24412/2226-0757-2023-2-44-52.
21. Zhitkova YuV, Gasparyan AA, Saihunov MV, et al. Observational study of the efficacy and safety of the drug Ampasse in patients with moderate cognitive impairment in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(10):75-80. (In Russ.)]. doi: 10.17116/jnevro202312310175.
22. Granzotto A, Canzoniero LMT, Sensi SL. A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade. Front Mol Neurosci. 2020 Nov 26;13:600089. doi: 10.3389/fnmol.2020.600089.
23. Levin OS. Diagnosis and treatment of cognitive impairment and dementia in clinical practice. Moscow: MEDpress-inform; 2019. (In Russ.)].
24. Gasiorowska A, Wydrych M, Drapich P, et al. The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. Front Aging Neurosci. 2021 Jul 13;13:654931. doi: 10.3389/fnagi.2021.654931.
25. Kiselev AV, Kotov AS, Mikhaleva MG, et al. Ampakines — a promising approach to neuroprotection. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(9):54-62. (In Russ.)]. doi: 10.17116/jnevro202212209154.
26. Kiselev AV, Vostrikova EV, Kalinina TS, Stovbun SV. A randomized, double-blind, placebo-controlled study of the efficacy and safety of ampasse in the treatment of chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):21-25. (In Russ.)]. doi: 10.17116/jnevro201911904121.
27. Skoromets AA, Kotov SV, Voronkov PB, et al. Efficacy and safety of treatment with ampasse: the results of a randomized, double-blind, placebo-controlled trial in patients with chronic cerebrovascular disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5):26-32. (In Russ.)]. doi: 10.17116/jnevro202112105126.
28. Belskaya GN, Sakharova EV, Kiryanova EA, et al. Possibilities of neuroprotective therapy in patients with chronic cerebral ischemia. "Neurology and Neurosurgery Eastern Europe". 2024;14(2):175182. (In Russ.)]. doi: 10.34883/PI.2024.14.2.046.
29. Yagudina RI, Kulikov AYu, Krylov VA, et al. Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):60-68. (In Russ.)]. doi:10.17116/jnevro201911907174.
30. Levin OS, Voznyuk IA, Illarioshkin SN, et al. Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9):121-130. (In Russ.)]. doi: 10.17116/jnevro2023123091121.
Review
For citations:
Kiselev A.V., Khokhlov A.L., Stovbun S.V., Speshilova S.A., Lileeva E.G. Clinical and economic aspects of chronic cerebral ischemia treatment. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2024;(4):46-54. (In Russ.) https://doi.org/10.37489/2588-0519-2024-4-46-54. EDN: NHHOEW
Views:
306
Email this article 